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doi:10.1
1014Objectives: Our objective was to compare effectiveness and safety of a simplified approach for removing
retroperitoneal tumors with extensive cavoatrial involvement using beating-heart cardiopulmonary bypass
(CPB) versus hypothermic circulatory arrest (HCA).
Methods: From January 1984 to January 2009, 144 patients underwent radical nephrectomy and inferior vena
caval tumor thrombectomy, 56 (39%) using CPB and 88 (61%) HCA. Compared with HCA patients, CPB
patients were of similar age (62  10 vs 60  11 years, P ¼ .4) and gender (39% vs 39% female, P>.9),
with similar stroke history (3.6% vs 2.3%, P ¼.6), but had less pulmonary disease (18% vs 33%, P ¼ .06)
and lower preoperative creatinine concentration (1.3  0.72 vs 1.5  0.86 mg $ dL1, P ¼ .04).
Results: Complete tumor removal was achieved in all patients by both strategies. Compared with HCA proce-
dures, CPB times were shorter (50  33 vs 94  40 minutes, P<.0001). CPB patients required fewer blood
transfusions (36% no transfusion vs 17%, and 45%4 units vs 72%; P¼ .003) and had no statistical difference
in morbidity, including reoperation for bleeding (3.8% vs 8.0%, P ¼ .3), renal failure requiring dialysis (3.6%
vs 10%, P¼ .14), respiratory insufficiency (21% vs 19%, P¼ .8), sepsis (5.4% vs 10%, P¼ .3), stroke (5.4%
vs 1.1%, P ¼ .13), and in-hospital mortality (7.1% vs 13%, P ¼ .3). Ten-year survival (22% vs 22%, P>.9)
and freedom from cancer recurrence (24% vs 28%, P ¼ .8) were similar.
Conclusions: Radical nephrectomy and removal of inferior vena caval tumor–thrombus can be simply,
effectively, and safely performed with beating-heart CPB, avoiding the deleterious effects of HCA and providing
clinical benefit without increasing morbidity or mortality. (J Thorac Cardiovasc Surg 2012;143:1014-21)Retroperitoneal tumors, especially renal cell carcinoma,
tend to spread into the venous system, growing toward
the inferior vena cava (IVC).1 In advanced stages, they
spread extensively into the suprahepatic IVC and right
atrium (level III/IV),2 initiating thrombus formation. Ad-
junct cardiopulmonary bypass (CPB) with hypothermic
circulatory arrest (HCA) has been the standard technique
for providing a virtually bloodless surgical field for suc-
cessful tumor removal.3 However, it is associated with long
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The Journal of Thoracic and Cardiovascular Surcardiopulmonary complications, and end-organ dysfunction,
leading to substantial morbidity and mortality.1,3
Beginning in the 1990s, we have explored a simplified al-
ternative surgical and perfusion technique using beating-
heart CPB without circulatory arrest (Figure 1). Purposes
of this study were to (1) detail this alternative approach to
treating retroperitoneal tumors with extensive cavoatrial in-
volvement, (2) address its advantages and limitations, and
(3) assess its effectiveness and safety compared with HCA.PATIENTS AND METHODS
Patients
From January 1984 to January 2009, 144 patients at Cleveland Clinic
had adjunct CPB for resection of primary retroperitoneal renal tumors
with level III/IV tumor–thrombus extension. Of these, 56 (39%) underwent
resection using CPB (CPB group) and 88 (61%) using HCA (HCA group).
Age of the CPB group was similar to that of the HCA group (62 10 vs 60
 11 years, P ¼ .4), as was gender (39% vs 39% female, P>.9) and his-
tory of stroke (3.6% vs 2.3%, P ¼ .6). However, CPB patients had lower
preoperative serum creatinine levels (1.3  0.72 vs 1.5  0.86 mg $ dL1,
P ¼ .04) and less chronic obstructive pulmonary disease (18% vs 33%,
P ¼ .06) (Table 1).
Preoperative demographic and comorbidity data and postoperative
complications until time of patient discharge were obtained from the pro-
spective Cardiovascular Information Registry, supplemented by medical
record review. The Institutional Review Board of the Cleveland Clinic ap-
proved collecting and using these data for research, with patient consent
waived.gery c May 2012
FIGURE 1. Time trends of cardiopulmonary bypass (CPB) versus hypo-
thermic circulatory arrest (HCA) for inferior vena cava tumor operations.
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
HCA ¼ hypothermic circulatory arrest
IVC ¼ inferior vena cava
PFO ¼ patent foramen ovale
SVC ¼ superior vena cava
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DMaximum cephalic intravascular tumor extent was classified according
to guidelines developed by Neves and Zincke2: level I, in the IVC at the re-
nal vein; level II, to the infrahepatic IVC; level III, to the retrohepatic IVC;
and level IV, to the supradiaphragmatic IVC or right atrium. Tumor extent
in all patients in our study was level III or IV.
Perfusion and Operative Techniques
Objectives.
1. Provide a bloodless surgical field for safe, complete removal of primary
tumor and its IVC/right heart tumor–thrombus extension by:
 Avoiding life-threatening pulmonary and systemic embolization of
fragmented tumor–thrombus
 Securing adequate vessel control (lumbar, adrenal, and suprahepatic
veins) for reduction of blood loss and effective blood salvage
2. Resolve or palliate IVC obstruction symptoms
3. Improve survival
Preoperative assessment and indications. Imaging studies to
assess extent of the primary tumor and cavoatrial involvement included
chest radiography, computed tomography of the chest and abdomen, selec-
tive renal and vena caval angiography, cardiac catheterization, echocardi-
ography, and magnetic resonance angiography. Since the advent of
intraoperative transesophageal echocardiography, it has been routinely
used to confirm intravascular tumor–thrombus location, identify occur-
rence of distal embolization, assess completeness of resection, diagnose
a patent foramen ovale (PFO) or atrial septal defect, detect intracardiac
air during CPB, and monitor cardiac performance.
The decision to use adjunct CPB was based on proximity of the vena
caval tumor–thrombus to the major hepatic veins and the cephalic supra-
diaphragmatic extension of the tumor. In general, venous thrombi at or
above the level of the major hepatic veins were referred for CPB.
Surgical preparation. Early in the experience, preoperative selec-
tive renal artery ethanol embolization was performed the day before sur-
gery according to surgeon preference (n ¼ 60), but this is no longer our
practice.
We have previously described the surgical technique for renal cell and
IVC tumor–thrombus removal with HCA.3 With either technique, opera-
tions are performed through 2 incisions: a transverse laparotomy (chevron
incision) and a median sternotomy (Figure 2), without dividing the dia-
phragm. Pericardial and peritoneal cavities are approached separately,
without connecting them. This approach provides adequate exposure, facil-
itates healing, and decreases potential for hypoperfusion and necrosis of the
triple point where both incisions are connected. After exposure of the
kidney and a variable length of the infrarenal and suprarenal IVC, nephrec-
tomy is performed to allow better access to, and exposure of, the IVC at the
level of the renal veins and retrohepatic segment. Local regional lympha-
denectomy is performed when preoperative or intraoperative findings
suggest lymph node involvement. Thereafter, the IVC is exposed for tumor
thrombectomy, and meticulous hemostasis in the retroperitoneum is ob-
tained before initiating CPB.
Perfusion strategies. Systemic heparinization (activated clotting
time>500 seconds) is established by administering 300 IU $ kg1. DistalThe Journal of Thoracic and Carvenous return is diverted by IVC cannulation (22F-24F) between bifurca-
tion and renal veins, and proximal return is diverted by right atrial cannu-
lation (24F-28F) directed toward the superior vena cava (SVC) or by direct
SVC cannulation with a right-angled 24F cannula. The ascending aorta is
cannulated with a 24F arterial cannula (Figure 3) with bicaval cannulation.
The IVC cannulation site is inferior to the intra-abdominal tumor. These 2
cannulas drained most of the venous return from the upper and lower body,
but additionally, 2 cardiotomy suckers were used to drain blood from the
right atrium and opened IVC to optimize visualization. Blood was filtered
through a 40-mm leukocyte reducing filter (LukoGuard LGB; Pall Corpo-
ration, East Hills, NY) interposed in the arterial line. A blood-salvage sys-
temwas used to assist in maintaining a bloodless field as well as to conserve
blood.
HCA strategy. CPB is established and the body cooled to 19C while
retrograde cardioplegic solution is administered. A steroid and barbiturate
are administered and ice is packed around the head for even cooling of the
brain, after which CPB is stopped and the blood volume is drained into
a reservoir. HCA is maintained while tumor–thrombus is being removed
from the atrium, proximal IVC, and abdominal IVC.
CPB strategy. CPB is initiated with mild systemic hypothermia (32C-
34C) and beating heart (no aortic clamp or cardioplegic cardiac arrest). So
that a near-bloodless field can be obtained for a simultaneous abdominal
IVC and right atrial approach, a carefully executed strategy for diverting
systemic venous return from the operative area is necessary.
IVC flow must be diverted upstream of the renal veins and blood from
tributaries in the operative area (open IVC) removed to provide adequate
visualization for tumor removal. Blood from the right atriumwill also enter
the operative area unless diverted.
Venous and arterial cannulation is performed in similar fashion as for
HCA. With transesophageal echocardiography for visual guidance and
care taken not to dislodge the tumor, the SVC and infrarenal IVC blood
flow is diverted through their respective venous cannulas, as is contralat-
eral renal vein blood flow. Then simultaneous incisions are made in the
right atrium and longitudinally in the anterolateral aspect of the IVC
(Figure 3).
Hepatic venous return is cleared with the aid of a vacuum-assisted suc-
tion device placed in the retrohepatic IVC, and coronary sinus and upper
body venous return are cleared by a similar device placed in the right
atrium, achieving a clear operative field for complete tumor removal
with minimal blood loss (Figure 3). Blood cleared in this fashion is
processed through a blood-salvage system before being returned to the
perfusion circuit.diovascular Surgery c Volume 143, Number 5 1015
TABLE 1. Patient characteristics according to perfusion strategy
Variable n*
CPB (n ¼ 56)
no. (%) n*
HCA (n ¼ 88)
no. (%) P
Demographics
Age (y), mean  SD 56 62  10 88 60  11 .4
Female 56 22 (39) 88 34 (39) >.9
Cardiovascular comorbidity
Previous cardiac operation 51 4 (7.8) 39 5 (13) .4
Previous MI 51 9 (18) 39 5 (13) .6
Heart failure 51 4 (7.8) 39 4 (10) .7
Atrial fibrillation/flutter 51 1 (2.0) 39 0 (0) .4
Previous stroke 56 2 (3.6) 88 2 (2.3) .6
Carotid disease 51 6 (12) 39 1 (2.6) .11
Peripheral arterial disease 51 7 (14) 39 2 (5.1) .18
Hypertension 50 30 (60) 38 24 (63) .8
Noncardiac comorbidity
Chronic renal disease 56 4 (7.1) 88 14 (16) .12
Smoking 49 31 (63) 36 20 (56) .5
COPD 45 8 (18) 75 25 (33) .06
Diabetes mellitus 51 7 (14) 39 10 (26) .15
Cancer 56
Histopathologic cell type 56 88
Renal 53 (95) 82 (93) .7
Adrenocortical carcinoma 2 (3.6) 1 (1.1) .6
Sarcoma 1 (1.8) 2 (2.3) >.9
Primitive neuroectodermaltumor 0 (0) 1 (1.1) >.9
Malignant fibroushistiocytoma 0 (0) 1 (1.1) >.9
Pheochromocytoma 0 (0) 1 (1.1) >.9
Pathologic classification
pT 56 85
2b 1 (1.8) 2 (2.4) .8
3b 11 (20) 8 (9.4) .08
3c 39 (70) 70 (82) .08
4 5 (8.9) 5 (5.9) .5
pN1 56 10 (18) 84 11 (13) .4
pM1 56 15 (27) 85 18 (21) .4
Tumor size (cm), mean  SD 54 9.4  3.9 75 10  4.6 .7
CPB, Cardiopulmonary bypass; HCA, hypothermic circulatory arrest; SD, standard deviation; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease.
*Patients with data available.
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DTumor removal. Through an oblique right atrial incision, the interior
of the right atrium, tricuspid valve and subvalvular apparatus, and proximal
IVC are explored, and controlled mobilization and removal of tumor–
thrombus is performed under direct visualization. The tumor is carefully
peeled away from the right atrial wall and IVC simultaneously and re-
moved en bloc through the cavotomy. In case of dense adherence, an end-
arterectomy spatula is used to peel the thrombus off the IVC endothelium.
The vena cavotomy and tumor-filled renal vein ostium are excised with the
tumor–thrombus. In the setting of adherent tumor–thrombus or invasion
into the IVC wall, the IVC wall is also resected with the tumor–thrombus.
In cases of tumor–thrombus extension into the pulmonary artery, an access
incision is made in the pulmonary trunk proximal to its bifurcation.
Intraoperative assessment of complete tumor resection is performed un-
der direct visualization of the right atrial wall as well as the intrahepatic and
infrahepatic IVC, and by advancing a balloon or Foley catheter from the
abdominal IVC to the right atrium, or performing an index finger maneu-
ver, to confirm a clean resection.
Because of IVC dilatation, its remnant lumen after removal of the tumor
is of normal diameter in most patients, permitting cavotomy closure with
a running 4-0 monofilament polypropylene suture technique without1016 The Journal of Thoracic and Cardiovascular Surnarrowing the lumen. If more than half the IVC circumference is resected,
satisfactory IVC size can be achieved by patch reconstruction with autolo-
gous or bovine pericardium, or polytetrafluoroethylene (PTFE; W. L. Gore
and Associates, Inc, Flagstaff, Ariz).
Concomitant procedures. In the event a PFO or atrial septal de-
fect is present or the tumor extends into the right ventricle, or if there is
need to perform concomitant cardiac procedures, the heart is arrested
with cold blood cardioplegic solution (4C) for tumor removal and surgical
correction of associated cardiac disease. Those patients with pulmonary tu-
mor embolus usually require HCA to remove emboli from the pulmonary
artery branches.
After closure of vascular and cardiac incisions, patients are rewarmed
and weaned from CPB. Anticoagulation is reversed by protamine adminis-
tration, and after satisfactory hemostasis is achieved, incisions are closed in
standard fashion.Data Analysis
Categorical variables were compared using Fisher’s exact or c2 tests, as
appropriate, and continuous variables were compared using the Wilcoxongery c May 2012
FIGURE 2. Surgical exposure. Adequate exposure of retroperitoneal tumor and caval tumor–thrombus requires a median sternotomy to expose the right
atrium (A) and a tranverse laparotomy (chevron incision) with mobilization of the parietocholic fascia to access the retroperitoneal tumor and inferior vena
cava (B).
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Drank sum test. Time-related events were analyzed nonparametrically by the
Kaplan-Meier method and parametrically by a multiphase hazard model.4
Follow-up. Systematic cross-sectional follow-up was performed in
January and February 2011 to assess cancer recurrence and vital status.
Among patients in the HCA group, 12 were lost to follow-up. Median
follow-up timewas 0.77 year; 25% still at risk of recurrence were followed
up more than 22 years and 10%more than 24 years. Among patients in the
CPB group, 9 were lost to follow-up. Median follow-up was 0.83 year;
25% still at risk of recurrence were followed up more than 13 years and
10% more than 14 years. For patients with metastatic (pM1) disease at re-
section, recurrence was defined as a new site of metastasis.
The Social Security Master Death File was used to supplement this
cross-sectional follow-up for vital status.5,6 Median follow-up was 1.3
years; 25%were still alivemore than 14 years and 10%more than 22 years
after operation.
Data Presentation
Continuous variables are summarized by mean  standard deviation or
by median and 15th and 85th percentiles, consistent with 1 standard de-
viation. Categorical data are summarized by frequencies and percentages.
All analyses were performed using SAS (SAS, Inc., Cary, NC) statistical
software (version 9.1).
RESULTS
Effectiveness
Complete tumor resection was achieved in all patients by
both surgical strategies.
Safety
Patients in the CPB group had shorter CPB times (50 
33 vs 94 40 minutes, P<.0001) and no HCA time versus
22 11minutes in the HCA group. Both groups had similarThe Journal of Thoracic and Carmyocardial ischemic times (15th, 50th, and 85th percen-
tiles, 0/12/54 versus 19/32/52 minutes; P¼ .2). Myocardial
arrest was not necessary for tumor removal in the CPB
group; it was used for concomitant coronary artery bypass
grafting in 7 (13%) patients versus 1 (1.0%) in the HCA
group, and for PFO closure in 3 (1 before tumor removal),
accounting for similarity of myocardial ischemic times.
CPB patients received fewer blood transfusions than
HCA patients (no red blood cells in 36% vs 17%,
P ¼ .003) (Table 2). Although postoperative complications
were fewer in CPB patients (27% vs 34%, P ¼ .4), with
lower occurrence of renal failure requiring dialysis (3.6%
vs 18%, P ¼ .14) and hospital mortality (7.1% vs 13%,
P ¼ .3), these findings could be due to chance. From
2002 to 2009, hospital mortality for patients in the CPB
group was 3.4% (1/29 patients; 68% confidence limits
0.7%-11%).
CPB patients experienced more perioperative strokes
(5.4% vs 1.1%, P ¼ .13), but this, too, could be due to
chance (Table 3). PFO was present in all 3 cases, undiag-
nosed preoperatively. Two were discovered by transesopha-
geal echocardiography after discontinuing CPB and were
associated with left ventricular air. Although the PFOs
were closed, the patients had watershed infarcts on postop-
erative computed tomography. In the third patient, the PFO
was identified before CPB, the heart arrested, and the PFO
closed. Nevertheless, a small lacunar infarct of uncertain
age was detected by magnetic resonance imaging, and the
transient defect completely resolved before discharge.diovascular Surgery c Volume 143, Number 5 1017
TABLE 2. Blood product use
Blood product
CPB (n ¼ 56) HCA (n ¼ 88)
n* No. (%) n* No. (%)
RBC units 56 87
0 20 (36) 15 (17)
1 3 (5.4) 3 (3.4)
2 7 (13) 2 (2.3)
3 1 (1.8) 4 (4.6)
4 25 (45) 63 (72)
Any FFP plasma 56 18 (32) 83 48 (58)
Any platelets 56 15 (27) 82 48 (59)
CPB, Cardiopulmonary bypass;HCA, hypothermic circulatory arrest; RBC, red blood
cell; FFP, fresh frozen plasma. *Patients with data available.
FIGURE 3. Perfusion technique. Both perfusion strategies use the same cannulation procedures: 2 venous cannulas (A) and 1 aortic cannula and arterial
filter (B). For beating-heart cardiopulmonary bypass, 2 additional pump suckers (C) are used to create a bloodless surgical field. A blood-salvage system (D)
is also used for blood conservation.
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DLength of intensive care unit stay was similar between
groups (median 3 days in both groups, P¼ .6), as was post-
operative length of stay (8.5 days in the CPB group vs 10
days in the HCA group, P ¼ .2).
Of patients in the CPB group, 30 had at least 1 recognized
cancer recurrence, and in the HCA group, 46 experienced
a recurrence. In both groups, distant metastases predomi-
nated, with recurrence in the liver more frequent in the
HCA group (33% vs 10% of those with recurrences,
P ¼ .03) and recurrence in bone more common in the CPB
group (43% vs 13% of those with recurrences, P ¼ .003)
(Table 4). Recurrence at multiple sites was more common
in the CPB group (50% vs 24% of those with recurrences,
P¼ .02). However, overall freedom from cancer recurrence
was similar between groups: 57%, 30%, 24%, and 20% in
the CPB group versus 55%, 31%, 28%, and 27% in the
HCA group (P[log–rank] ¼ .7) at 1, 5, 10, and 15 years,
respectively (Figure 4). Survival after operation was also
similar: 58%, 33%, 22%, and 17% in the CPBgroup versus
57%, 32%, 22%, and 17% in the HCA group (P[log–rank]
> .9) at 1, 5, 10, and 15 years, respectively (Figure 5).
DISCUSSION
We have described a simplified approach to perfusion
support for complete removal of tumor–thrombus involving
the IVC that employs beating-heart CPB. Effectiveness of
complete tumor–thrombus removal was comparable with
that for HCA,with decreased transfusion needs and a similar
safety profile.1018 The Journal of Thoracic and Cardiovascular SurPerfusion Strategies
Some reports with a limited number of patients have ad-
vocated using continuous beating-heart CPB to avoid HCA
for complete removal of retroperitoneal tumors with exten-
sive cavoatrial involvement.7,8 We moved progressively
over the past 2 decades from HCA to continuous CPB,
which provides adequate exposure and a near-bloodless
field for the surgeon while avoiding complexity and risks
of HCA. Although femoral vein cannulation can adequately
drain the lower body, we do not use this technique because it
requires an additional incision, with potential associated
complications including lymphocele, infection, and com-
partment syndrome, which could compromise postopera-
tive recovery.gery c May 2012
TABLE 3. Postoperative complications
Complication
CPB (n ¼ 56)
no. (%)
HCA (n ¼ 88)
no. (%) P
Hospital mortality 4 (7.1) 11 (13) .3
Reoperation for bleeding 2 (3.6) 7 (8.0) .3
Renal failure requiring dialysis 2 (3.6) 9 (10) .14
Respiratory insufficiency 12 (21) 17 (19) .8
Stroke 3 (5.4) 1 (1.1) .13
Myocardial infarction 0 (0) 1 (1.1) .4
Sepsis 3 (5.4) 9 (10) .3
Any complication 15 (27) 30 (34) .4
CPB, Cardiopulmonary bypass; HCA, hypothermic circulatory arrest.
TABLE 4. Sites of recurrent cancer
Recurrence site*
CPB (n ¼ 30y)
no. (%)
HCA (n ¼ 46y)
no. (%) P
Local 13 (43) 12 (26) .12
Lymphatic 4 (13) 6 (13) >.9
Regional 1 (3.3) 0 (0) .2
Distant 3 (10) 6 (13) .8
Lung 8 (27) 12 (26) >.9
Liver 3 (10) 15 (33) .03
Brain 6 (20) 5 (11) .3
Bone 13 (43) 6 (13) .003
Skin 1 (3.3) 2 (4.3) .8
Multiple recurrence sites 15 (50) 11 (24) .02
CPB, cardiopulmonary bypass; HCA, hypothermic circulatory arrest. *Because of
multiple recurrence sites, percentages add to more than 100%. yPatients who had
a recurrence.
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DEffectiveness
Regardless of perfusion technique used, complete surgi-
cal resection of level III/IV tumor–thrombus requires 2mul-
tidisciplinary teams to perform a major operation with
complete exposure and dissection in the abdomen and
thorax.7-9
For patients with more limited IVC tumor extension, re-
cent publications have described surgical approaches to
avoid sternotomy and CPB.10-13 Some of these involve
temporary occlusion of the proximal IVC with a balloon,
venovenous bypass and limited anticoagulation, or IVC
staple ligation and en bloc resection of level III tumor–
thrombus occluding the IVC in patients who have adequate
collaterals and no edema in the lower limbs. Although
these strategies are reported to have good results for level
II/III tumors, they would not be considered for patients
with level IV cavoatrial extension, for which a more
extensive resection is necessary. Direct vision, which we
advocate, decreases risk of distal embolization that may
result when mobilization is done by blind dissection.
Safety
Outcomes. Our study covers a period of 25 years during
which evolution of anesthetic techniques, surgical tech-
niques, and postoperative care led to improved operative
results. This must be kept in mind when interpreting our
overall hospital mortality of 7.5% and 13%; more recent
series of level III/IV tumor resection report mortalities
between 3% and 10%.14,15 Other authors have reported
mortality of up to 40% if the IVC tumor extended above
the diaphragm in the IVC.16,17
The HCA group had longer CPB times, primarily owing
to the time required to cool and later rewarm the patient, al-
though a more complex resection may have also contributed
to these findings. In addition, these patients had a mean
HCA time of 22 11minutes, during which end-organ vital
function can be preserved only by decreasing systemic
metabolic requirements.
CPB is associated with transient platelet dysfunction,18
and HCA may increase this effect and further affect coagu-
lation.19 Not surprisingly, patients in the HCA group wereThe Journal of Thoracic and Carmore likely to undergo reoperation for bleeding and re-
quired more blood product transfusions than patients in
the CPB group, as others have reported.20 Mounting evi-
dence points to deleterious effects of allogeneic transfusion
that have been associated with both tumor recurrence21,22
and postoperative infection.23,24
The most frequent postoperative complication in both
groups was respiratory insufficiency, likely owing to the ex-
tent of median laparotomy and sternotomy incisions. Thus,
pain control and adequate respiratory therapy with incentive
spirometry are essential in postoperative management.
We observed less renal dysfunction and sepsis in the CPB
group. Only 1 patient in our entire series experienced a peri-
operative myocardial infarction (HCA group), comparing
favorably with previous reports25; this is probably related
to thorough preoperative cardiac assessment in all patients,
with coronary catheterization performed preoperatively
when indicated.
Stroke in the early CPB experience was associated with
a PFO in all 3 cases. We recommend preoperative and intra-
operative imaging for PFO diagnosis. If it is present, the
heart should be arrested and the PFO closed before com-
mencing tumor removal.
The only concomitant cardiac operation was coronary
artery bypass grafting in 8 patients. This did not increase
postoperative complications or mortality.
Postoperative length of stay was similar in both groups,
comparing favorably with earlier reports that describe lon-
ger hospital stays even in patients not undergoing HCA.26
Cancer spread during CPB. CPB requires reinfusion of
salvaged blood, possibly increasing the chances of tumor
metastasis more than with HCA. Although a higher propor-
tion of patients in the CPB group had multiple recurrence
sites, overall likelihoods of cancer recurrence and survival
were similar to those of the HCA group. Gray and col-
leagues27 studied biomarker cancer recurrence in patients
undergoing radical retropubic prostatectomy with intrao-
perative cell salvage and autotransfusion using a leukocytediovascular Surgery c Volume 143, Number 5 1019
FIGURE 4. Freedom from cancer recurrence after operation stratified by perfusion strategy. Each symbol represents a death, vertical lines 68% confidence
limits, and numbers in parentheses patients remaining at risk. Solid line is parametric estimate enclosed within 68% confidence bands. For pM1 patients,
recurrence was defined as a new site of metastasis. CPB, Resection using continuous cardiopulmonary bypass and a beating heart; HCA, resection using
hypothermic circulatory arrest.
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Dreduction filter as the sole blood management technique.
They compared this with that of patients who predonated
1 to 3 units of autologous blood. Cell salvage did not appear
to be associated with an increased risk of early biochemical
progression. Nieder and colleagues28 reported that routine
use of cell-salvaged blood did not adversely affect midtermFIGURE 5. Survival after operation stratified by perfusion strategy. Format is as
a beating heart; HCA, resection using hypothermic circulatory arrest.
1020 The Journal of Thoracic and Cardiovascular Sursurvival (3-year follow-up) of 378 patients undergoing
radical cystectomy.
Catling and colleagues29 found that patients undergoing
surgery for gynecologic cancers demonstrated circulating
cells at the time of removal, and in more than half, cancer
cells were present in blood aspirated with a cell-salvagein Figure 4.CPB,Resection using continuous cardiopulmonary bypass and
gery c May 2012
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Dsystem. A leukodepleting filter effectively removed these
cells in all cases. We have used an intraoperative blood-
salvage system since 2000 in both CPB and HCA patients,
in keeping with current guidelines for urologic cancers.27-29
Blood is suctioned from the operative field and through
a leukocyte depletion filter (LeukoGuard LGB) in the
arterial line before it is returned to the patient.LIMITATIONS
This single-institution observational clinical study
spanned 25 years, so evolving approaches to surgical man-
agement and postoperative patient care may have con-
founded the results. Although we have compiled extensive
data on each patient with respect to his or her cancer, we
have limited the presentation of these data to major patho-
logic characterization and to cancer recurrence and sur-
vival. In addition, HCA was used only for more difficult
cases in more recent times, which may have biased our
results in favor of CPB.CONCLUSIONS
Radical removal of retroperitoneal tumors with extensive
cavoatrial involvement can be simply, effectively, and
safely performed with beating-heart CPB, avoiding the
deleterious effects of HCA. Performing additional cardiac
procedures does not adversely affect operative outcomes.
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